Total amount: € 0,00
HOW TO ORDER
A Journal on Endocrine System Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2017 Mar 01
Copyright © 2017 EDIZIONI MINERVA MEDICA
Comparison of curative effect of 131I and antithyroid drugs in Graves’ disease: a meta analysis
Ju YUAN 1 , Xiuqing LU 2 ✉, Yan YUE 1
1 Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou, China; 2 Department of Neurology, Henan Province Hospital of TCM, Zhengzhou, China
BACKGROUND: Radioactive 131I is currently reported to be a potential effective intervention for Graves’ Disease treatment in China. Whether 131I treatment was associated with effective outcome or reduced risk of side effects, reccurence rate remained unknown.
EVIDENCE ACQUISITION: Eligible studies were selected from Chinese VIP, Wangfang, CNKI databases using the keywords “Iodine” and “Graves Disease”. Finally, 13 clinical trials met the inclusion criterion and were included this meta-analysis.
EVIDENCE SYNTHESIS: Our meta-analysis included 1355 patients diagnosed of Graves’ Disease with regular anti-thyroid drugs oral administration and 1320 patients with 131I therapy. The results showed that there was significant symptom improvement with radioactive iodine intervention (Odd Ratio (OR)=4.50, 95% CI [3.55, 5.71], P<0.01). 3 studies mentioned side effects, 6 mentioned reccurence rate and another 6 mentioned hypothyroidism. The ORs and 95%CIs for these subgroups were 0.12 [0.06, 0.21], 0.08 [0.05, 0.13] and 2.27 [1.77, 2.92] respectively. It means a significant reduction of side effects and reccurence rate but increased hypothyroidism after 131I intervention in Graves’ Disease.
CONCLUSION: Treatment with 131I was associated with better clinical outcome; it reduced side effects and reccurence rate but increased hypothyroidism in Graves’ Disease.
KEY WORDS: 131I - Antithyroid drugs - Grave's disease - Meta-analysis - Clinic outcome